From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 2.22
Pain Relevance 0.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (CTSA) mitochondrion (CTSA) small molecule metabolic process (CTSA)
endoplasmic reticulum (CTSA) nucleolus (CTSA) nucleus (CTSA)
Anatomy Link Frequency
myocytes 1
B lymphocytes 1
CTSA (Homo sapiens)
Pain Link Frequency Relevance Heat
Fibrositis 58 94.52 High High
bradykinin 4 89.84 High High
anesthesia 2 88.60 High High
imagery 6 55.28 Quite High
Enkephalin 1 25.00 Low Low
Pain 5 20.28 Low Low
depression 7 5.00 Very Low Very Low Very Low
peripheral neuropathy 6 5.00 Very Low Very Low Very Low
antagonist 4 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 83 99.18 Very High Very High Very High
Sleep Disorders 62 94.52 High High
Death 11 85.40 High High
Pick Disease Of The Brain 5 75.00 Quite High
Gangliosidoses 1 74.36 Quite High
Stress 20 72.36 Quite High
Congenital Anomalies 4 71.60 Quite High
Neointima 9 68.96 Quite High
Neurologic Manifestations 30 67.44 Quite High
Virus Diseases 1 59.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fig. 1Institute for Translational Medicine and Therapeutics (ITMAT) Centers proposed within the Penn/CHOP CTSA grant and the new cores supporting the Translational Research Center.
Gene_expression (grant) of CTSA
1) Confidence 0.43 Published 2008 Journal AAPS J Section Body Doc Link PMC2751447 Disease Relevance 0 Pain Relevance 0
Perhaps the most intriguing observation from the current study is the detection of cells that express the endothelial lineage marker GSL I-B4[19], [20] within the NI of both non-stented and stented allograft segments, as well as stented native arteries.
Gene_expression (express) of GSL
2) Confidence 0.24 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2267220 Disease Relevance 0.07 Pain Relevance 0
Several animal studies also showed that depletion of GSL could be lethal or lead to neurological disturbance, and substrate reduction therapy should be aimed to reduce biosynthesis of GSL to a degree that can be tolerated by cells (Radin 1996).
Gene_expression (biosynthesis) of GSL
3) Confidence 0.20 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.31 Pain Relevance 0
In immunohistochemistry, cathepsin A was detected in myocytes of atrial tissue.
Gene_expression (detected) of cathepsin in myocytes
4) Confidence 0.14 Published 2002 Journal Hypertension Section Abstract Doc Link 12019279 Disease Relevance 0 Pain Relevance 0.08
These results are consistent with our hypothesis and with GSLs being centrally involved in the pathogenesis of NPC disease, and they suggest that drugs inhibiting GSL synthesis could have a similar ameliorating effect on the human disorder.
Gene_expression (synthesis) of GSL associated with disease
5) Confidence 0.08 Published 2001 Journal Curr. Biol. Section Abstract Doc Link 11525744 Disease Relevance 0.50 Pain Relevance 0.09
-galactosidase, cathepsin, LC3, and Lyso Tracker) and enhanced expression of autophagic genes at both transcriptional and translational levels, indicating the presence of autophagy [9].
Gene_expression (expression) of cathepsin
6) Confidence 0.05 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875645 Disease Relevance 0.72 Pain Relevance 0.32
The inhibition of GSL synthesis by miglustat has been demonstrated to reduce pathological intracellular lipid storage, improve fluid-phase endosomal uptake and normalize lipid transport in peripheral blood B lymphocytes of NP-C patients.44 This leads to a reduction of the potentially neurotoxic accumulation of gangliosides GM2 and GM3, lactosylceramide and glucosylceramide, and may prevent further neuronal damage.
Gene_expression (synthesis) of GSL in B lymphocytes
7) Confidence 0.05 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2781062 Disease Relevance 0.30 Pain Relevance 0
Miglustat is a small iminosugar molecule that acts as a competitive inhibitor of the enzyme glucosylceramide synthase, which catalyzes the first committed step in glycosphingolipid (GSL) synthesis, the glycosylation of ceramide.30 This inhibits the synthesis of all glucosylceramide-derived glycosphingolipids.
Gene_expression (synthesis) of GSL
8) Confidence 0.04 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2781062 Disease Relevance 0.33 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools